461 related articles for article (PubMed ID: 29218503)
1. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
[TBL] [Abstract][Full Text] [Related]
3. Psychotropics regulate Skp1a, Aldh1a1, and Hspa8 transcription--potential to delay Parkinson's disease.
Lauterbach EC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():236-9. PubMed ID: 23046827
[TBL] [Abstract][Full Text] [Related]
4. A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.
Fishman-Jacob T; Youdim MBH
J Neural Transm (Vienna); 2024 Jun; 131(6):675-707. PubMed ID: 37644186
[TBL] [Abstract][Full Text] [Related]
5. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.
Fishman-Jacob T; Reznichenko L; Youdim MB; Mandel SA
J Biol Chem; 2009 Nov; 284(47):32835-45. PubMed ID: 19748892
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes.
Grünblatt E; Mandel S; Jacob-Hirsch J; Zeligson S; Amariglo N; Rechavi G; Li J; Ravid R; Roggendorf W; Riederer P; Youdim MB
J Neural Transm (Vienna); 2004 Dec; 111(12):1543-73. PubMed ID: 15455214
[TBL] [Abstract][Full Text] [Related]
7. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
[TBL] [Abstract][Full Text] [Related]
10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
11. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
[TBL] [Abstract][Full Text] [Related]
12. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
13. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
17. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
18. Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A.
Mandel SA; Fishman-Jacob T; Youdim MB
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S148-51. PubMed ID: 20082978
[TBL] [Abstract][Full Text] [Related]
19. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease in patients with Alzheimer's disease.
Leverenz J; Sumi SM
Arch Neurol; 1986 Jul; 43(7):662-4. PubMed ID: 3729742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
